Details of the Drug Combinations

General Information of This Drug (ID: DMW7K39)

Drug Name

Pyrotinib DMW7K39

Synonyms

UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Capecitabine + Pyrotinib	DCGPYQN	Capecitabine	HER2 Positive Metastatic Breast Cancer	[2]
Leuprolide + Pyrotinib	DCMOQG0	Leuprolide	Acute HIV Infection	[3]
Vinorelbine + Pyrotinib	DCG0HI7	Vinorelbine	Metastatic Breast Cancer	[4]
Capecitabine + Pyrotinib	DC3S2UI	Capecitabine	HER2 Positive Metastatic Breast Cancer	[5]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02422199) A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
3	ClinicalTrials.gov (NCT05087706) Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland CancerMAPS?Unknown status
4	ClinicalTrials.gov (NCT04963595) Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
5	ClinicalTrials.gov (NCT02973737) A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer